Drug Development – Page 5

BioMarin’s R&D Chief Warns of Innovation Slowdown Amid NIH Funding Cuts

10 months ago talkbio0Tagged BioMarin, biomedical innovation, Drug Development, Hereditary Diseases, NIH Mouse, research partnerships

BioMarin, NIH funding, biomedical innovation, genetic diseases, drug development, research partnerships

Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond

10 months ago talkbio0Tagged Alzheimer 's disease, Amyotrophic Lateral Sclerosis, Clinical Trials, Drug Development, Duchenne, Neoplasms, Neuroscience discipline, Schizophrenia

Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology

Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment

10 months ago talkbio0Tagged Antisense, Biogen, Drug Development, Epilepsy, Infantile Severe Myoclonic Epilepsy, Infrequent, Oligonucleotides, pharmaceutical partnership, Stoke, Zorevunersen

Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership

AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies

10 months ago talkbio0Tagged AbbVie, Collaboration, Drug Development, engagers, Immunotherapy, Neoplasms, T-Lymphocyte, tumor-activated

AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development

Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects

10 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Capsid, Cu-Zn Superoxide Dismutase, Drug Development, Effect, gene therapy, off-target, payload, Preclinical, RNA, Small Interfering, Tracer, VY9323

SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay

Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

10 months ago talkbio0Tagged Drug Development, Failure (biologic function), Kinevant, namilumab, Phase 2 clinical trial, Roivant, Sarcoidosis, Pulmonary

Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure

Eli Lilly Streamlines Pipeline, Removing Alzheimer’s and Obesity Candidates in Q4 2024

10 months ago talkbio0Tagged Alzheimer 's disease, Ceperognastat, Clinical Trials, Drug Development, Eli, Eli Lilly, Obesity, pipeline update

Eli Lilly, pipeline update, Alzheimer’s disease, obesity, ceperognastat, clinical trials, drug development

Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension

10 months ago talkbio0Tagged Clinical Failure, Drug Development, IkT-001Pro, Inhibikase, Parkinson 's disease, Phase 2 Clinical Trials, Pulmonary arterial hypertension, risvodetinib

Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro

Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology

11 months ago talkbio0Tagged AbbVie, Biotechnology, Drug Development, Immunology, molecular glue, Neomorph, Neoplasms, pharmaceutical partnership, Protein Degradation, Metabolic

Neomorph, AbbVie, molecular glue degraders, oncology, immunology, protein degradation, drug development, biotechnology, pharmaceutical partnership.

Servier and Google Cloud Extend Partnership to Accelerate AI-Powered Drug Development

11 months ago talkbio0Tagged Artificial Intelligence, digital transformation, Drug Development, generative, Google Cloud, Pharmaceutical Research, R&D, Servier, therapeutic solutions

Servier, Google Cloud, AI, drug development, pharmaceutical research, digital transformation, R&D, generative AI, gen AI, therapeutic solutions.